trial · primary record
Ivosidenib 500mg
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 156 |
| Primary completion | 2030-11-26 |
| Primary endpoint | Progression-free survival (PFS) based on Blinded Independent Central Reviewer (BICR) assessment in Grade 1 and Grade 2 participants |
| Registry ID | NCT06127407 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:40:50.532Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06127407
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.